---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-23-000103"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2023-06-21T23:59:59+00:00"
generated_at: "2026-06-13T19:50:53.386732+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Kiora Pharma 2023 annual meeting results: all proposals approved

## Summary
- Kenneth Gayron, Aron Shapiro, Praveen Tyle elected as Class II directors (3-year term, through 2026).
- Non-binding advisory vote on executive compensation passed: 243,595 for, 43,492 against, 8,996 abstain.
- Ratification of Haskell & White LLP as independent auditor ratified: 798,689 for, 14,659 against, 19,738 abstain.
- Total shares voted at meeting: approximately 1.1M (including broker non-votes).

## SEC filing metadata
- accession: 0001372514-23-000103
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2023-06-21T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000103/0001372514-23-000103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000103/kprx-20230621.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-23-000103
- JSON: https://secwatch.observer/filing/0001372514-23-000103.json
- Plain text: https://secwatch.observer/filing/0001372514-23-000103.txt

## Key facts
- Shareholder Votes
  KIORA PHARMACEUTICALS INC shareholders approved Approval, on a Non-Binding Basis, of the Compensation of the Company’s Executive Officers at the 2023-06-21 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-21
  source text: The compensation of the Company’s executive officers as disclosed in the Company’s definitive proxy statement filed with respect to the Annual Meeting was approved on a non-binding basis. The results of the vote were as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 243,595 43,492 8,996 537,003
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000103/0001372514-23-000103-index.htm
- Shareholder Votes
  KIORA PHARMACEUTICALS INC shareholders approved Ratification of the Appointment of Haskell & White LLP as the Company’s independent registered public accounting firm at the 2023-06-21 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-21
  source text: The appointment of Haskell & White LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified. There were no broker non-votes on this proposal. The results of the vote were as follows: Votes For Votes Against Votes Abstained 798,689 14,659 19,738
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000103/0001372514-23-000103-index.htm
- Shareholder Votes
  KIORA PHARMACEUTICALS INC shareholders approved Election of Kenneth Gayron, Aron Shapiro and Praveen Tyle, Ph.D. as Class II Directors at the 2023-06-21 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-21
  source text: Kenneth Gayron, Aron Shapiro and Praveen Tyle, Ph.D. were elected as Class II Directors for a three-year term, such term to continue until the annual meeting of stockholders in 2026 and until such directors’ successors are duly elected and qualified or until their earlier resignation or removal. Due to the plurality election, votes could only be cast in favor of or withheld from the nominee and thus votes against were not applicable. The results of the election were as follows: Name Votes For Votes Withheld Broker Non-Votes Kenneth Gayron 271,239 24,844 537,003 Aaron Shapiro 266,275 29,808 537,003 Praveen Tyle, Ph.D. 264,242 31,841 537,003
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000103/0001372514-23-000103-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.